LONDON A French biotech firm is hoping to gain approval within months for a nuclear medicine targeting the type of cancer that killed Steve Jobs.
LONDON British drugmakers on Wednesday accused Theresa May's Conservative government of breaking a manifesto commitment to improve access to new medicines, following approval of new cost rules that take effect on April 1.
LONDON AstraZeneca's ovarian cancer drug Lynparza slashed the risk of disease progression in a closely watched clinical trial, boosting its profile against rivals within the novel PARP inhibitor drug class.
LONDON Scientists have taken a big step toward designing complex forms of life from scratch by constructing five new artificial chromosomes of baker's yeast, representing a third of the micro-organism's genome, or genetic blueprint. | Video
Novo Nordisk's new chief executive is looking at making acquisitions to broaden the Danish drugmaker's product line-up, in a change of tack that reflects a need for fresh sources of growth at the world's biggest diabetes company.
Scientists have found signs of brain damage that could cause dementia in a handful of former soccer players, fuelling worries about the danger of frequent knocks from heading the ball or colliding with others on the field. | Video
LONDON Scientists have found signs of brain damage that could cause dementia in a handful of former soccer players, fuelling worries about the danger of frequent knocks from heading the ball or colliding with others on the field. | Video
LONDON A newly unearthed essay by Winston Churchill shows Britain's wartime leader was uncannily prescient about the possibility of alien life on planets orbiting stars other than the Sun.
LONDON Treatment with two important cancer drugs is about to get much cheaper in Europe with a cut-price copy of Roche's blood cancer drug Rituxan likely to hit the market imminently followed by a rival to its breast cancer medicine Herceptin.
LONDON A group of academic researchers has demanded an end to cancer medicines costing more than $100,000 a year and proposed a new model of low-cost drug development that would capitalize on recent advances in science.